Debiopharm, a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, has launched the IDEAL Japan initiative, a new program designed to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 year...